Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib

Published:October 18, 2017DOI:


      • Progression-free survival (PFS) was associated with metastases at diagnosis and KIT exon 9 mutation.
      • rs1870377 in KDR and rs1570360 in VEGFA were associated with worse PFS.
      • rs4149117 in SLCO1B3 showed a trend for an association with PFS.



      Imatinib 400 mg per day is first-line therapy for patients with gastrointestinal stromal tumours (GISTs). Although clinical benefit is high, progression-free survival (PFS) is variable. This study explores the relationship of single nucleotide polymorphisms (SNPs) in genes related to imatinib pharmacokinetics and pharmacodynamics and PFS in imatinib-treated patients with advanced GIST.


      In 227 patients a pharmacogenetic pathway analysis was performed. Genotype data from 36 SNPs in 18 genes were tested in univariate analyses to investigate their relationship with PFS. Genetic variables which showed a trend (p < 0.1) were tested in a multivariate model, in which each singular SNP was added to clinicopathological factors.


      In univariate analyses, PFS was associated with synchronous metastases (p = 0.0008) and the mutational status (p = 0.004). Associations with rs1870377 in KDR (additive model, p = 0.0009), rs1570360 in VEGFA (additive model, p = 0.053) and rs4149117 in SLCO1B3 (mutant dominant model, 0.027) were also found. In the multivariate model, significant associations and trends with shorter PFS were found for synchronous metastases (HR 1.94, p = 0.002), KIT exon 9 mutation (HR 2.45, p = 0.002) and the SNPs rs1870377 (AA genotype, HR 2.61, p = 0.015), rs1570360 (AA genotype, HR 2.02, p = 0.037) and rs4149117 (T allele, HR 0.62, p = 0.083).


      In addition to KIT exon 9 mutation and synchronous metastases, SNPs in KDR, VEGFA and SLCO1B3 appear to be associated with PFS in patients with advanced GIST receiving 400-mg imatinib. If validated, specific SNPs may serve as predictive biomarkers to identify patients with an increased risk for progressive disease during imatinib therapy.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Baccarani M.
        • Pileri S.
        • Steegmann J.L.
        • Muller M.
        • Soverini S.
        • Dreyling M.
        Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2012; 23 (vii72–vii7)
        • The ESMO/European Sarcoma Network Working Group
        Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2014; 25 (iii21–iii6)
        • Mathijssen R.H.
        • Sparreboom A.
        • Verweij J.
        Determining the optimal dose in the development of anticancer agents.
        Nat Rev Clin Oncol. 2014; 11: 272-281
        • Debiec-Rychter M.
        • Sciot R.
        • Le Cesne A.
        • Schlemmer M.
        • Hohenberger P.
        • van Oosterom A.T.
        • et al.
        KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
        Eur J Cancer. 2006; 42: 1093-1103
        • Kim D.H.
        • Sriharsha L.
        • Xu W.
        • Kamel-Reid S.
        • Liu X.
        • Siminovitch K.
        • et al.
        Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
        Clin Cancer Res. 2009; 15: 4750-4758
        • Hirota S.
        • Isozaki K.
        • Moriyama Y.
        • Hashimoto K.
        • Nishida T.
        • Ishiguro S.
        • et al.
        Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
        Science. 1998; 279: 577-580
        • Hirota S.
        • Ohashi A.
        • Nishida T.
        • Isozaki K.
        • Kinoshita K.
        • Shinomura Y.
        • et al.
        Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.
        Gastroenterology. 2003; 125: 660-667
        • Janeway K.A.
        • Kim S.Y.
        • Lodish M.
        • Nose V.
        • Rustin P.
        • Gaal J.
        • et al.
        Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.
        Proc Natl Acad Sci U S A. 2011; 108: 314-318
        • Van Glabbeke M.
        • Verweij J.
        • Casali P.G.
        • Le Cesne A.
        • Hohenberger P.
        • Ray-Coquard I.
        • et al.
        Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.
        J Clin Oncol. 2005; 23: 5795-5804
        • Eechoute K.
        • Sparreboom A.
        • Burger H.
        • Franke R.M.
        • Schiavon G.
        • Verweij J.
        • et al.
        Drug transporters and imatinib treatment: implications for clinical practice.
        Clin Cancer Res. 2011; 17: 406-415
        • Angelini S.
        • Pantaleo M.A.
        • Ravegnini G.
        • Zenesini C.
        • Cavrini G.
        • Nannini M.
        • et al.
        Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy.
        Pharmacol Res. 2013; 68: 1-6
        • Ravegnini G.
        • Sammarini G.
        • Angelini S.
        • Hrelia P.
        Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.
        Expert Opin Drug Metab Toxicol. 2016; 12: 733-742
        • Oosterhuis J.W.
        • Coebergh J.W.
        • van Veen E.B.
        Tumour banks: well-guarded treasures in the interest of patients.
        Nat Rev Cancer. 2003; 3: 73-77
        • Whirl-Carrillo M.
        • McDonagh E.M.
        • Hebert J.M.
        • Gong L.
        • Sangkuhl K.
        • Thorn C.F.
        • et al.
        Pharmacogenomics knowledge for personalized medicine.
        Clin Pharmacol Ther. 2012; 92: 414-417
        • Baak-Pablo R.
        • Dezentje V.
        • Guchelaar H.J.
        • van der Straaten T.
        Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification.
        J Mol Diagn. 2010; 12: 746-749
        • Barrett J.C.
        • Fry B.
        • Maller J.
        • Daly M.J.
        Haploview: analysis and visualization of LD and haplotype maps.
        Bioinformatics. 2005; 21: 263-265
        • Purcell S.
        • Neale B.
        • Todd-Brown K.
        • Thomas L.
        • Ferreira M.A.
        • Bender D.
        • et al.
        PLINK: a tool set for whole-genome association and population-based linkage analyses.
        Am J Hum Genet. 2007; 81: 559-575
        • McAuliffe J.C.
        • Lazar A.J.
        • Yang D.
        • Steinert D.M.
        • Qiao W.
        • Thall P.F.
        • et al.
        Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
        Clin Cancer Res. 2007; 13: 6727-6734
        • Kim D.H.
        • Xu W.
        • Kamel-Reid S.
        • Liu X.
        • Jung C.W.
        • Kim S.
        • et al.
        Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.
        Ann Oncol. 2010; 21: 1179-1188
        • Kang B.W.
        • Kim J.G.
        • Chae Y.S.
        • Bae H.I.
        • Kwon O.
        • Chung H.Y.
        • et al.
        Clinical significance of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 gene polymorphisms in patients with gastrointestinal stromal tumors.
        Asia Pac J Clin Oncol. 2014; 10: e40-e45
        • Glubb D.M.
        • Cerri E.
        • Giese A.
        • Zhang W.
        • Mirza O.
        • Thompson E.E.
        • et al.
        Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer.
        Clin Cancer Res. 2011; 17: 5257-5267
        • Ravegnini G.
        • Nannini M.
        • Zenesini C.
        • Simeon V.
        • Sammarini G.
        • Urbini M.
        • et al.
        An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure.
        Angiogenesis. 2017; 20: 139-148
        • Hu S.
        • Franke R.M.
        • Filipski K.K.
        • Hu C.
        • Orwick S.J.
        • de Bruijn E.A.
        • et al.
        Interaction of imatinib with human organic ion carriers.
        Clin Cancer Res. 2008; 14: 3141-3148
        • Lima L.T.
        • Bueno C.T.
        • Vivona D.
        • Hirata R.D.
        • Hirata M.H.
        • Hungria V.T.
        • et al.
        Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
        Hematology. 2015 Apr; 20: 137-142
        • Nambu T.
        • Hamada A.
        • Nakashima R.
        • Yuki M.
        • Kawaguchi T.
        • Mitsuya H.
        • et al.
        Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia.
        Biol Pharm Bull. 2011; 34: 114-119
        • Liegl B.
        • Kepten I.A.
        • Le C.
        • Zhu M.
        • Demetri G.D.
        • Heinrich M.C.
        • et al.
        Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
        J Pathol. 2008; 216: 64-74
        • Dulucq S.
        • Bouchet S.
        • Turcq B.
        • Lippert E.
        • Etienne G.
        • Reiffers J.
        • et al.
        Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.
        Blood. 2008; 112: 2024-2027
        • Ni L.N.
        • Li J.Y.
        • Miao K.R.
        • Qiao C.
        • Zhang S.J.
        • Qiu H.R.
        • et al.
        Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia.
        Med Oncol. 2011; 28: 265-269
        • Takahashi N.
        • Miura M.
        • Scott S.A.
        • Kagaya H.
        • Kameoka Y.
        • Tagawa H.
        • et al.
        Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.
        J Hum Genet. 2010; 55: 731-737
        • van Huis-Tanja L.
        • Kweekel D.
        • Gelderblom H.
        • Koopman M.
        • Punt K.
        • Guchelaar H.J.
        • et al.
        Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples.
        Pharmacogenomics. 2013; 14: 2005-2012